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analysis combinedwith an elegant set ofmolecular, cellular and electro-
physiological experiments helped the group to visualize a genotype-
phenotype relationship. This relationship was apparent in clinical ob-
servations and detectable by means of in vitro investigations into chan-
nel properties, calcium signaling, steroidogenic enzyme expression and
aldosterone secretion into cell culture supernatants. While the patientsCACNA1H
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Aldosterone secretion is under the control of potassium, renin and
angiotensin (Ang II). Consequently, concepts to explain autonomous al-
dosterone secretion as the basis for primary aldosteronism (PA) includ-
ed the presence of stimulating autoantibodies to the Ang II type 1
receptor (AT1R), gain-of-function mutations in the AT1R and aberrant
expression of G-protein-coupled membrane receptors that are respon-
sive to alternative stimuli and have access to the cellular AT1R signaling
apparatus (Luft, 2013,Mazzuco et al., 2010). However, while these ideas
are great the power to explaining the pathophysiology of PA remained
small. The breakthrough came with the systematic clariﬁcation of sig-
naling pathways which control aldosterone secretion, the application
of whole exome sequencing to adrenal disease and the discovery that
a mutated channel which is associated with familial and sporadic
forms of PA results in an increase in intracellular calcium (Fig. 1) (Choi
et al., 2011). The same group also discovered that a mutation in
CACNA1H, encoding the voltage-gated T-type calcium channel Cav3.2,
is associated with an early onset form of primary hyperaldosteronism
(Scholl et al., 2015). The data in the EBioMedicine paper by Daniil et
al. strongly supports the disease-driving character of such mutations
allowing calcium to inﬂuxmore readily into the aldosterone-producing
adrenal zona glomerulosa cell. And the paper adds familial and sporadic
variants of PA with altered CACNA1H sequence to our knowledge data-with different forms of primary
.
m.2016.10.002.
. This is an open access article underbase (Daniil et al., 2016). Systematic clinical work and modern genetic
with amildmutation did not, the subject with the severe CACNA1Hmu-
tation had early onset PA and multiplex developmental disorder. Inter-
estingly, pathological neurologic features had been reported to occur in
patients with PA due to a CACNA1D mutation which is also known to
strongly affect intracellular calcium within zona glomerulosa cells
(Scholl et al., 2013). The tumors of such patients are comparably small
but show strong expression of aldosterone synthase and suppression
of renin. Interestingly, it was suggested that some mutations may se-
verely interfere with the cellular calcium homeostasis and even cause
the death of an affected adrenocortical cell thus preventing the cell
from developing hyperplastic or tumorous tissue.
However, less severe aberrations, including somemutations in the G
protein-activated inward rectiﬁer potassiumchannel 4 (GIRK4) potassi-
um channel, seem to be associatedwith amilder phenotype of PA, larger
tumors and expression of aldosterone synthase in the remainingnormal
zona glomerulosa tissue as a sign of non-(full) suppression of renin and
angiotensin. This may explain why in tumors of patients with
malfunctioning GIRK4 channels, the 11beta-hydroxylase is expressed
at higher levels within the aldosterone-producing tumors and that
such patients form more so-called “adrenal hybrid steroids” than pa-
tients with aldosteronomas due to CACNA1D mutations (Fig. 1)
(Williams et al., 2016).
Along these lines, it seems to be very difﬁcult to characterize the
point of crossover from a single-nucleotide polymorphism to amild dis-
ease-triggering mutation by means of such studies. An astonishing ob-
servation in this context is that mutations which are associated with
the formation of aldosterone-producing adenomas were also observed
in bilaterally hyperplastic adrenals and may even appear within differ-
ent nodules in one adrenal gland although each nodule seems to har-
bour only one single mutation (Fernandes-Rosa et al., 2015). As such
it remains open how channelopathies associated with PA –whether in-
born or acquired – allow the affected adrenal cell to proliferate and
break away fromaldosterone-producing cell clusters in order to formal-
dosterone-producing adenomas.
So far, conventional cell culture studies did not provide the data to
reach conclusions on how such mutations cause growth andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Both, corticotropin (ACTH) and angiotensin II (Ang II) stimulate adrenal steroidogenesis via binding to theirG-protein coupled receptors,MC2RandAT1R, respectively. Separation of
glucocorticoid and mineralocorticoid synthesis occurs through different signaling pathways and suppression of the ACTH-stimulated adenylyl cyclase (AC) and protein kinase A activities
when Ang II binds to its receptor. Ang II is generated when renin is secreted, leading to elevate intracellular calcium and expression of the aldosterone synthase (CYP11B2). However, the
action of Ang II is bypassed in a state of hyperkalemiawhen potassium is prevented from efﬂux through theGIRK4 channel causing depolarization of the adrenal zona glomerulosa cell. This
mechanism serves to regulate the organism's external potassium balance through an increase in aldosterone. Inherited or sporadic mutations in several ion channels that are employed in
the regulation of the intracellular calcium concentration may lead to overactivity of calmodulin kinase and upregulation of CYP11B2, thereby achieving autonomy from control by renin
and Ang II: primary aldosteronism. When aldosterone synthesis occurs independently from Ang II the inﬂuence of ACTH on steroidogenesis is conserved. Expression of both aldosterone
synthase and 11beta-hydroxylase (CYP11B1) results in generation of so-called “adrenal hybrid steroids”which is dependent on the activity balance in the signaling pathways. This sketch
is a further development of illustrations by Choi et al. (2011) and Zennaro et al. (2013).
16 H.S. Willenberg / EBioMedicine 13 (2016) 15–16proliferation of adrenal cortical cells. This may be because the inﬂuence
of corticotropin, adrenal blood ﬂow and tissue gradients also seem to
play an important role in organ physiology and cell differentiation
(Dringenberg et al., 2013). Therefore, while this study bridged the gap
between clinical observations, the molecular background, its impact
on cell physiology and aldosterone secretion, further such studies
should address the question how the molecular changes promote cell
proliferation and adrenal tumor formation.
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